<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24359" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Livedoid Vasculopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Majmundar</surname>
            <given-names>Vidit D.</given-names>
          </name>
          <aff>Civil Hospital Ahmedabad</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Syed</surname>
            <given-names>Hasnain A.</given-names>
          </name>
          <aff>Sheikh Zayed Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baxi</surname>
            <given-names>Kalgi</given-names>
          </name>
          <aff>SMT NHL MEDICAL COLLEGE AND SVP HOSPITAL</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vidit Majmundar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hasnain Syed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kalgi Baxi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24359.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Livedoid vasculopathy is a rare vasculopathy typically characterized by bilateral lower limb lesions. The interplay of increased thrombotic activity, decreased fibrinolytic activity, and endothelial damage is believed to cause thrombus formation in the capillary vasculature. This&#x000a0;activity delves into the multifaceted nature of the condition, emphasizing its association with hypercoagulability, thrombus formation, and endothelial damage, factors contributing to its diagnostic complexity and potential misdiagnosis.&#x000a0;Learners will gain critical insights into the diverse underlying etiologies linked to increased thrombotic activity and decreased fibrinolytic activities, significantly impacting the course of the disease and prognosis. Moreover, this session emphasizes the pivotal role of an interprofessional approach in promptly evaluating and effectively managing livedoid vasculopathy to enhance patient outcomes.</p>
        <p>By exploring the gender and age predilections&#x02014;3 times more prevalent in females aged 15 to 50&#x02014;attendees will grasp the demographic nuances of this condition. The session underscores the necessity of precise lesion identification and differentiation from similar lower limb lesions and emphasizes the significance of skin biopsy for accurate diagnosis confirmation. Furthermore, attendees will review current management strategies, encompassing general measures like smoking cessation and wound care, alongside pharmacological interventions such as anticoagulants and antiplatelets that have demonstrated efficacy. Additionally, novel and experimental therapies promising advancements in resistant cases will be elucidated, fostering a deeper understanding of emerging treatment modalities for livedoid vasculopathy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology and epidemiology of livedoid vasculopathy.</p></list-item><list-item><p>Assess patients with livedoid vasculopathy through appropriate history, physical, and laboratory evaluation.&#x000a0;</p></list-item><list-item><p>Compare the treatment and management options available for livedoid vasculopathy.</p></list-item><list-item><p>Apply effective strategies to improve care coordination among interprofessional team members to facilitate positive outcomes for patients&#x000a0;with livedoid vasculopathy.&#x000a0;</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24359&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24359">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24359.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Livedoid vasculopathy is a rare vasculopathy typically characterized by bilateral lower limb lesions. The condition is believed to be caused by thrombus formation in the capillary vasculature due to&#x000a0;increased thrombotic activity, decreased fibrinolytic activity, and endothelial damage.</p>
        <p>Livedoid vasculopathy is 3 times more common in females than in males, especially in patients aged 15 to 50 years. Management involves identifying the lesion and differentiating it from other lower limb lesions, along with a skin biopsy to confirm the diagnosis.</p>
        <p>There is no definitive first-line&#x000a0;treatment, but general measures such as smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.&#x000a0;Several newer and experimental therapies have shown promising results in resistant cases.<xref ref-type="bibr" rid="article-24359.r1">[1]</xref><xref ref-type="bibr" rid="article-24359.r2">[2]</xref><xref ref-type="bibr" rid="article-24359.r3">[3]</xref>&#x000a0;</p>
        <p>In the past, livedoid vasculopathy has also been referred to as livedo&#x000a0;vasculitis, livedoid vasculitis, and livedo reticularis with summer ulceration.<xref ref-type="bibr" rid="article-24359.r4">[4]</xref></p>
      </sec>
      <sec id="article-24359.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Vasculopathy occurs when a thrombus forms in the arterial lumen leading to compromised blood flow. It is distinct from vasculitis, which refers to primary inflammation of the vessel wall followed by fibrinoid necrosis. Livedoid vasculopathy is usually associated with phenomena that cause hypercoagulability and thrombus formation, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Conditions associated with stasis:</bold> Chronic venous hypertension of the limbs, varicose veins&#x000a0;(vasculopathy is not generally surrounded by livedo reticularis)&#x000a0;<xref ref-type="bibr" rid="article-24359.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Autoimmune connective tissue diseases:</bold> Systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome, rheumatoid arthritis, scleroderma, mixed connective tissue disease.</p>
          </list-item>
          <list-item>
            <p><bold>Thrombophilias:</bold> Inherited causes&#x000a0;(factor V Leiden variant,&#x000a0;prothrombin&#x000a0;gene <italic toggle="yes">G20210A</italic> mutation, protein C,&#x000a0;protein S, and&#x000a0;antithrombin deficiency, etc); acquired causes&#x000a0;(acquired homocysteinemia, cryoglobulinemia, cryofibrinogenemia, acquired antiphospholipid antibody syndrome)</p>
          </list-item>
          <list-item>
            <p><bold>Neoplasms:</bold> Myeloproliferative disorders, paraproteinemia, etc</p>
          </list-item>
          <list-item>
            <p><bold>Idiopathic causes</bold>&#x000a0;<xref ref-type="bibr" rid="article-24359.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24359.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Livedoid vasculopathy is a rare diagnosis with an approximate incidence of 1&#x000a0;in 1,00,000 per year. It is 3 times more common in females than in males. Most of the patients are 15 to 50 years old.<xref ref-type="bibr" rid="article-24359.r1">[1]</xref>&#x000a0;It is now established that there is&#x000a0;an increased&#x000a0;incidence&#x000a0;of livedo vasculopathy during the summer months. It is also more frequently seen in pregnant women.<xref ref-type="bibr" rid="article-24359.r6">[6]</xref></p>
      </sec>
      <sec id="article-24359.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of livedoid vasculopathy can be explained by increased thrombotic and decreased fibrinolytic activity along with endothelial cell damage.</p>
        <p>Biochemical mechanisms involving defects in the proteins and enzymes involved in the coagulation and fibrinolysis pathways can lead to increased platelet and fibrin-rich thrombi in the capillaries leading to its typical cutaneous manifestations.<xref ref-type="bibr" rid="article-24359.r2">[2]</xref></p>
        <p>Some patients with livedoid vasculopathy have an associated condition that predisposes them to occlusion of the small vessels of the lower leg. An example of this is when homocysteinemia leads to DNA hypomethylation and prevents the action of histone deacetylase, which leads to transcriptional repression along with increased oxidant stress on cells due to increased expression of <italic toggle="yes">p66shc</italic> in endothelial cells.<xref ref-type="bibr" rid="article-24359.r7">[7]</xref><xref ref-type="bibr" rid="article-24359.r8">[8]</xref></p>
      </sec>
      <sec id="article-24359.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Livedoid vasculopathy is usually a clinical diagnosis, but a skin biopsy from a red papule or the edge of a new ulcer supports it.&#x000a0;The most characteristic histological findings consist of thickening or hyalinization of superficial dermal vessels along with intraluminal fibrin deposits. Red blood cell extravasation and perivascular lymphocytic infiltration may be associated.<xref ref-type="bibr" rid="article-24359.r1">[1]</xref><xref ref-type="bibr" rid="article-24359.r9">[9]</xref></p>
        <p>A direct&#x000a0;immunofluorescence is often performed, showing the deposition of&#x000a0;immunoglobulin&#x000a0;and complement&#x000a0;components in the superficial, mid-dermal, and deep dermal vasculature. However, these findings are neither characteristic nor diagnostic of livedoid vasculopathy.<xref ref-type="bibr" rid="article-24359.r10">[10]</xref></p>
      </sec>
      <sec id="article-24359.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The patient usually presents with a history of painful recalcitrant ulcers and whitish scars near the ankles, which are associated with a painful burning sensation. The prodrome of this burning pain is a pathognomonic feature in history. Usually, pure livedoid vasculopathy is a skin-limited manifestation; hence, no systemic symptoms are expected. However, lesions akin to livedoid vasculopathy are seen in autoimmune connective tissue diseases, antiphospholipid antibody syndrome, and inherited thrombophilia; hence, a detailed history focusing on these associated diseases must be elucidated.<xref ref-type="bibr" rid="article-24359.r11">[11]</xref></p>
        <p>Livedoid vasculopathy is characterized by punched-out ulcers in the perimalleolar area surrounded by lacy, reticular, reddish to violaceous streaks, also known as livedo reticularis.<xref ref-type="bibr" rid="article-24359.r12">[12]</xref> These ulcers heal, forming porcelain white scars surrounded by telangiectasias and represent the vestiges of cutaneous infarction due to disturbed capillary microcirculation. These scars are known as atrophie blanche or capillaritis alba and are not specific to livedoid vasculopathy. Ulcers characterize the active stage of the disease, whereas livedo reticularis and livedo racemosa (broken net pattern) are precursors to ulceration. Painful purpuric ulcers with reticular pattern of lower extremities (PPURPLE) sums up the entire clinical spectrum of this condition. Retiform or stellate purpura is considered a hallmark lesion.<xref ref-type="bibr" rid="article-24359.r13">[13]</xref>&#x000a0;Most commonly, lesions can be seen in&#x000a0;the perimalleolar area, but they can also be seen on the lower leg and foot. The disease is bilateral in most cases.<xref ref-type="bibr" rid="article-24359.r3">[3]</xref></p>
      </sec>
      <sec id="article-24359.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The approach for evaluation of a patient presenting with lesions suspicious of livedoid vasculopathy should focus on confirming the diagnosis, ruling out close differentials, and a workup for associated conditions.</p>
        <p>A skin biopsy, preferably a 3- to 4-mm punch biopsy from the margin of the ulcer or the surrounding livedo, is a must for confirming the diagnosis.</p>
        <p>Ankle-brachial pressure index and lower limb venous doppler should be done to rule out chronic venous insufficiency.</p>
        <p>Laboratory investigations should focus on ruling out the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypercoagulable states (eg, factor 5 Leiden mutation, platelet plug disorders, hyperhomocysteinemia, etc)</p>
          </list-item>
          <list-item>
            <p>Fibrinolytic disorders. (eg, protein C and protein S deficiency)</p>
          </list-item>
          <list-item>
            <p>Collagen vascular diseases (eg, SLE, scleroderma, antiphospholipid antibodies)</p>
          </list-item>
          <list-item>
            <p>Paraprotenemia&#x000a0;<xref ref-type="bibr" rid="article-24359.r3">[3]</xref><xref ref-type="bibr" rid="article-24359.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24359.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment approach for livedoid vasculopathy should aim at preventing ulceration, promoting rapid healing of existing ulcers, and pain relief.</p>
        <p>
<bold>General Measures</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pain management:</bold> Pain relief is achieved by the use of nonsteroidal antiinflammatory drugs (NSAIDs), tricyclic antidepressants like amitriptyline, gabapentin, pregabalin, and antiepileptics such as carbamazepine, as these drugs are known to relieve neuropathic pain.</p>
          </list-item>
          <list-item>
            <p><bold>Intravenous immunoglobulin (IVIG):</bold> Rapid relief of pain has been reported with the use of IVIG, which causes inhibition of thromboxane A2 and endothelin and thereby improves perfusion.</p>
          </list-item>
          <list-item>
            <p><bold>Wound care:</bold> General principles of wound healing and management should be followed.</p>
          </list-item>
          <list-item>
            <p>
<bold>Smoking cessation</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Compression therapy</bold>
</p>
          </list-item>
        </list>
        <p>
<bold>Specific Pharmacological Measures</bold>
</p>
        <p>There are no definitive therapeutic guidelines for the management of livedoid vasculopathy. However, a combination of anticoagulants, antiplatelet medications, fibrinolytic therapies, and anabolic steroids are reported to be efficacious&#x000a0;</p>
        <p>
<bold>Drugs by category</bold>
</p>
        <p>Examples of drugs used to treat&#x000a0;livedoid vasculopathy include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Anti-platelet agents:</bold> Aspirin (325 mg/day), dipyridamole, and pentoxifylline (400 mg/day)</p>
          </list-item>
          <list-item>
            <p><bold>Anticoagulants:</bold>&#x000a0;Low molecular weight heparin, warfarin (with monitoring for the international normalized ratio [INR] of 2.0-3.0), rivaroxaban (20 mg/day), and direct thrombin inhibitors such as dabigatran</p>
          </list-item>
          <list-item>
            <p><bold>Fibrinolytic therapies:</bold> Recombinant tissue plasminogen activator, danazol, and stanozolol&#x000a0;<xref ref-type="bibr" rid="article-24359.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Immunomodulatory and immunosuppressive agents:</bold>&#x000a0;IVIG, cyclosporine, doxycycline, dapsone (especially in myeloproliferative disorders), sulfasalazine, and psoralen plus ultraviolet A (PUVA)</p>
          </list-item>
          <list-item>
            <p><bold>Vasodilators:</bold>&#x000a0;Nifedipine, cilostazol</p>
          </list-item>
          <list-item>
            <p><bold>Other:</bold> Hyperbaric oxygen therapy, ketanserin (quinazoline), alprostadil (prostaglandin analog)&#x000a0;<xref ref-type="bibr" rid="article-24359.r1">[1]</xref><xref ref-type="bibr" rid="article-24359.r3">[3]</xref><xref ref-type="bibr" rid="article-24359.r16">[16]</xref><xref ref-type="bibr" rid="article-24359.r17">[17]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24359.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for livedoid vasculopathy include:</p>
        <p>
<bold>Livedo Reticularis With Ulceration</bold>
</p>
        <p>This active stage is mimicked by cutaneous polyarteritis nodosa (PAN) and often leads to a diagnostic dilemma. Cutaneous PAN is characterized by livedo racemosa, subcutaneous nodules, and starburst livedo. It is a medium-vessel cutaneous vasculitis. The presence of subcutaneous nodules, occasional digital gangrene, and histopathology aid in its diagnosis.</p>
        <p>
<bold>Atrophie Blanche</bold>
</p>
        <p>Porcelain white scars are seen in sickle cell disease, hydroxyurea ulcers, and malignant atrophic papulosis.</p>
        <p>
<bold>Other</bold>
</p>
        <p>Other close differentials are antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis, cutaneous small-vessel vasculitis, cryoglobulinemia, and Sneddon syndrome (livedo racemosa with cerebrovascular stroke).<xref ref-type="bibr" rid="article-24359.r3">[3]</xref><xref ref-type="bibr" rid="article-24359.r9">[9]</xref><xref ref-type="bibr" rid="article-24359.r17">[17]</xref><xref ref-type="bibr" rid="article-24359.r18">[18]</xref><xref ref-type="bibr" rid="article-24359.r19">[19]</xref></p>
      </sec>
      <sec id="article-24359.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of livedoid vasculopathy may vary widely among patients.&#x000a0;It is influenced by several factors, including the underlying cause, patients' treatment response, and associated conditions.</p>
        <p>
<bold>Key Considerations</bold>
</p>
        <p>
<bold>Chronic course</bold>
</p>
        <p>Livedoid vasculopathy often follows a chronic and relapsing course. Episodes of painful ulcers and skin lesions may recur intermittently, and the condition may persist over an extended period.</p>
        <p>
<bold>Underlying causes</bold>
</p>
        <p>Identifying and addressing underlying causes or associated conditions is crucial for prognosis. Livedoid vasculopathy can be primary (idiopathic) or secondary to various conditions, such as hypercoagulable states, vasculitis, or connective tissue disorders. The prognosis may be better if the underlying cause is effectively managed.</p>
        <p>
<bold>Complications</bold>
</p>
        <p>The development of complications, such as nonhealing ulcers, skin atrophy, or secondary infections, can impact prognosis. Early and appropriate management of complications is essential to prevent long-term sequelae.</p>
        <p>
<bold>Response to treatment</bold>
</p>
        <p>The response to treatment can significantly influence prognosis. Therapeutic approaches for livedoid vasculopathy may include anticoagulants, immunosuppressive agents, and supportive wound care. Finding the most effective treatment regimen may sometimes require a trial-and-error approach.<xref ref-type="bibr" rid="article-24359.r20">[20]</xref></p>
        <p>
<bold>Multidisciplinary care</bold>
</p>
        <p>Collaboration between dermatologists, rheumatologists, hematologists, and other specialists is often necessary for comprehensive care. A multidisciplinary approach can contribute to a more thorough evaluation and management plan, potentially improving prognosis.</p>
      </sec>
      <sec id="article-24359.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Livedoid vasculopathy mainly presents with ulcerative lesions in both lower limbs. Local complications like secondary skin infections that show typical signs of inflammation are commonly encountered. Other manifestations like pain (due to local hypoxic damage and cytokine reaction), secondary cutaneous hyperpigmentation (due to extravasation of erythrocytes along with hemosiderin deposition in the skin), and mononeuritis multiplex (due to thrombosis of vasa nervorum) and atrophic scarring of skin are seen.<xref ref-type="bibr" rid="article-24359.r1">[1]</xref></p>
      </sec>
      <sec id="article-24359.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is an important part of managing the disease. The patient should be educated about the importance of smoking cessation. Complying with the other general measures like compression stockings and wound care is also of utmost importance. Finally, the patient should be instructed about reporting urgently to the&#x000a0;clinician in cases of worsening symptoms.</p>
      </sec>
      <sec id="article-24359.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Livedoid vasculopathy is a challenging diagnosis. Surprisingly, the epidemiological data show a 5-year delay with adequate diagnosis and management of this condition. Therefore,&#x000a0;an interprofessional team&#x000a0;that includes nurses, primary clinicians, pharmacists, and&#x000a0;dermatologists should be educated about identifying this condition. Many of the patients&#x000a0;can be misdiagnosed. Hence, educating healthcare workers about identifying and performing routine workups before referring to the dermatologist is an important part of enhancing healthcare. Finally, the dermatologist should also know the importance of getting a skin biopsy of appropriate depth and dimensions to avoid missing the diagnosis.<xref ref-type="bibr" rid="article-24359.r1">[1]</xref></p>
      </sec>
      <sec id="article-24359.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24359&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24359">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/livedoid-vasculopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24359">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24359/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24359">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24359.s16">
        <fig id="article-24359.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Livedoid vasculitis Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Livedoid__vasculitis__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24359.s17">
        <title>References</title>
        <ref id="article-24359.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freitas</surname>
                <given-names>TQ</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Criado</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy: a compelling diagnosis.</article-title>
            <source>Autops Case Rep</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>e2018034</fpage>
            <pub-id pub-id-type="pmid">30101138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goerge</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].</article-title>
            <source>Hautarzt</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>627</fpage>
            <page-range>627-34; quiz 635</page-range>
            <pub-id pub-id-type="pmid">21786003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alavi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hafner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dutz</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sibbald</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Criado</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Senet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Callen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Romanelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kirsner</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>69</volume>
            <issue>6</issue>
            <fpage>1033</fpage>
            <page-range>1033-1042.e1</page-range>
            <pub-id pub-id-type="pmid">24028907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eswaran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Googe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vedak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marston</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Moll</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy: A review with focus on terminology and pathogenesis.</article-title>
            <source>Vasc Med</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>593</fpage>
            <page-range>593-603</page-range>
            <pub-id pub-id-type="pmid">36285834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segu&#x000ed;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Llamas-Velasco</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>993515</fpage>
            <pub-id pub-id-type="pmid">36569162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilgic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozcobanoglu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bozca</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Alpsoy</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>5Part A</issue>
            <fpage>588</fpage>
            <page-range>588-599</page-range>
            <pub-id pub-id-type="pmid">35024414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Cerbone</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Di Minno</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine, coagulation, platelet function, and thrombosis.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2000</year>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-54</page-range>
            <pub-id pub-id-type="pmid">11011842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Doshi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2022</year>
            <season>Nov-Dec</season>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>771</fpage>
            <page-range>771-774</page-range>
            <pub-id pub-id-type="pmid">36386750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Dermoscopic features of livedoid vasculopathy.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>96</volume>
            <issue>11</issue>
            <fpage>e6284</fpage>
            <pub-id pub-id-type="pmid">28296736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuttawong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chularojanamontri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trakanwittayarak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pinkaew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chanchaemsri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rujitharanawong</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>525</fpage>
            <page-range>525-531</page-range>
            <pub-id pub-id-type="pmid">32986882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy and its association with genetic variants: A systematic review.</article-title>
            <source>Int Wound J</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>616</fpage>
            <page-range>616-625</page-range>
            <pub-id pub-id-type="pmid">33686673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy presenting with leg ulcers.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>58</volume>
            <issue>11</issue>
            <fpage>2076</fpage>
            <pub-id pub-id-type="pmid">31220328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Criado</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Pagliari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>TCAB</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Pincelli</surname>
                <given-names>TPH</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>NYS</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>MSC</given-names>
              </name>
              <name>
                <surname>de Carvalho</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Abdalla</surname>
                <given-names>BMZ</given-names>
              </name>
              <name>
                <surname>Sotto</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation.</article-title>
            <source>Dermatol Ther</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>e14810</fpage>
            <pub-id pub-id-type="pmid">33496999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Criado</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Rivitti</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sotto</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Vasconcellos</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy: an intringuing cutaneous disease.</article-title>
            <source>An Bras Dermatol</source>
            <year>2011</year>
            <season>Sep-Oct</season>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>961</fpage>
            <page-range>961-77</page-range>
            <pub-id pub-id-type="pmid">22147037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>178</fpage>
            <page-range>178-183</page-range>
            <pub-id pub-id-type="pmid">32116074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rustin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Bunker</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Dowd</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin.</article-title>
            <source>Br J Dermatol</source>
            <year>1989</year>
            <month>Jan</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-5</page-range>
            <pub-id pub-id-type="pmid">2638912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasudevan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Neema</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Livedoid vasculopathy: A review of pathogenesis and principles of management.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>82</volume>
            <issue>5</issue>
            <fpage>478</fpage>
            <page-range>478-88</page-range>
            <pub-id pub-id-type="pmid">27297279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Sneddon's syndrome: a comprehensive review of the literature.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2014</year>
            <month>Dec</month>
            <day>31</day>
            <volume>9</volume>
            <fpage>215</fpage>
            <pub-id pub-id-type="pmid">25551694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mimouni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Rencic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nikolskaia</surname>
                <given-names>OV</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Nousari</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche.</article-title>
            <source>Br J Dermatol</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-94</page-range>
            <pub-id pub-id-type="pmid">12752140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24359.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramphall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rijal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ekladios</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mulayamkuzhiyil Saju</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mandal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kham</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Shahid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Venugopal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>e28485</fpage>
            <pub-id pub-id-type="pmid">36051980</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
